Skip to main content
PMC home page
NPJ Regenerative Medicine logoLink to NPJ Regenerative Medicine
. 2020 Sep 11;5:15. doi: 10.1038/s41536-020-00100-4

Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis

Julia Deinsberger 1,2,#, David Reisinger 1,#, Benedikt Weber 1,2,✉
PMCID: PMC7486930  PMID: 32983575

Abstract

Pluripotent stem cells (PSCs) hold great potential for novel therapeutic approaches to regenerate or replace functionally impaired tissues. Since the introduction of the induced pluripotent stem cell technology in 2006, the number of scientific publications on this topic has constantly been increasing. However, so far no therapy based on PSCs has found its way into routine clinical use. In this study, we examined research trends related to clinical trials involving PSCs based on data obtained from ClinicalTrials.gov, the ICTRP database from the World Health Organization, as well as from a search of all individual databases that are included in the ICTRP using a multistep search algorithm. Following a stringent inclusion/exclusion procedure 131 studies remained that could be classified as clinical trials involving PSCs. The magnitude of these studies (77.1%) was observational, which implies that no cells were transplanted into patients, and only a minority of studies (22.9%) were of an interventional study type. The number of clinical trials involving induced pluripotent stem cells (iPSCs, 74.8%) was substantially higher than the one involving embryonic stem cells (ESCs, 25.2%). However, the picture changes completely when focusing on interventional studies, where in the majority (73.3%) of cases ESCs were used. Interestingly, also the study duration was significantly shorter for interventional versus observational trials (p = 0.002). When focusing on the geographical study regions, it became obvious that the greatest part of all observational trials was performed in the USA (41.6%) and in France (16.8%), while the magnitude of interventional studies was performed in Asian countries (China 36.7%, Japan 13.3%, South Korea 10.0%) and in the field of ophthalmology. In summary, these results indicate that only a limited number of trials were focusing on the actual transplantation of PSCs into patients in a rather narrow field of diagnoses. The future will tell us, if the iPSC technology will ultimately overcome the current challenges and will finally make its way into routine clinical use.

Subject terms: Embryonic stem cells, Induced pluripotent stem cells

Introduction

Pluripotent stem cells are defined by their self-renewal capacity and ability to differentiate into any cellular phenotype of the human body1. This plasticity has generated significant hope for therapies that may enable repair of functionally impaired tissues2,3. Several studies involving embryonic stem cells (ESCs) have been performed showing initial clinical success4–6. However, the use of ESCs is limited by several hurdles. Most importantly, the derivation of ESCs is associated with the destruction of the human embryo at the blastocyst-stage, which is associated with ethical concerns7. Secondly, ESCs are isolated from pre-implantation blastocysts and are thus, by their nature, never of autologous origin, which may cause immunological rejection by the host. The generation of induced pluripotent stem cells (iPSCs) alleviated these two major obstacles and thus holds the potential to open up completely new therapeutic options. The essence of iPSCs is that a mature, finally differentiated cell is reprogrammed via insertion of a set of genes, generating a pluripotent cell line for a specific patient8. Since the first report on iPSCs by Yamanaka et al. in 20069, we have experienced publication of a plethora of studies involving preclinical in vitro10,11 and in vivo12–16 as well as first clinical studies in humans investigating the feasibility and safety of ESCs and iPSCs for therapeutic applications. Ongoing efforts to realize stem cell-based therapies for ophthalmic diseases and neurological disorders have so far shown promising results5,12,17–19. This rapid translation of the technology also supports the enormous potential and application range of pluripotent stem cell research8,20,21. However, the published information on trials is generally limited by a significant publication bias, implying that negative results may not be published at all. In addition, results may not be published due to a lack of interest by sponsoring institutions or they will be published in different languages. This is of particular interest as a growing body evidence has revealed genetic instability, epigenetic abnormalities and immunogenicity of iPSCs, raising safety concerns regarding clinical applications22–28. Additionally, pluripotent stem cells pose a considerable cancer risk in the recipient, firstly through potential teratoma formation and secondly due to genetic alterations as a consequence to the usage of integrating vectors creating a risk for reactivation of commonly used reprogramming factors (OCT4, SOX2, MYC, and KLF4), which are also highly expressed in various cancer types25,29.

The analysis of the ‘status quo’ of clinical trials on pluripotent stem cells would offer a comprehensive overview on the actual number and content of clinical trials involving this promising technology. Several studies focusing on the trends in stem cell research have been conducted so far30–33. However, these studies were either limited regarding the type of stem cell used, such as multipotent stem cells only33, or their search was conducted using only one database (mostly “ClinicalTrials.gov”)30–33. Even though “ClinicalTrials.gov”34 is the largest database for clinical trials and represented in over 200 countries around the globe, a search query in this database does not guarantee completeness. Therefore, we complemented our systematic search using the international clinical trials registry platform (ICTRP)35 from the Word Health Organization (WHO) and further individual databases contained in the ICTRP in order to achieve the most complete overview on clinical trials involving pluripotent stem cells. As part of this systematic analysis a particular focus was also put on the global distribution of the trials, the study type - observational versus interventional -, as well as on the number of patients enrolled.

Results

Results of the systematic multi-database search algorithm

In the database search using “ClinicalTrials.gov” 177 studies were identified when using the predefined search criteria. Out of those, 65 studies had to be excluded, because they did not involve pluripotent stem cells at all or their employment was optional. Three studies were excluded, because they had to be withdrawn before enrolling the first participant. Hence, 109 studies remained for further in-depth analysis. Searching the meta-database ICTRP using the same predefined search criteria added 21 additional clinical trials, which were not found in the search using “ClinicalTrials.gov”. The individual search of all databases that are included in the ICTRP did detect one additional relevant clinical trial in the “Australian New Zealand Clinical Trials Registry” (ANZCTR). Altogether, 131 clinical trials involving human pluripotent stem cells were identified and included into further in-depth analyses. For a detailed list of all trials please refer to Supplementary Table 1.

Global distribution of clinical trials involving pluripotent stem cells

All clinical trials were classified according to the country or area they were conducted in. Overall, 36% (47) of all trials were conducted in the USA, 15% (19) in France, 12% (16) in China (entire Chinese territory including Taiwan 14% (18)), 9% (12) in Japan, 6% (8) in the United Kingdom (UK), 6% (8) in Israel, 4% (5) in Germany, 2% (3) in South Korea, 2% (3) in Australia, 2% (3) in Pakistan, 2% (2) in Taiwan, 1% (1) in Brazil, 1% (1) in India, 1% (1) in Italy, 1% (1) in the Netherlands and 1% (1) in Iran (see Fig. 1a, b). The study could be classified as interventional trial in 22.9% (30) and as observational in 77.1% (101). When focusing on interventional studies (characterized by a (re-)transplantation of PSCs into humans), China was by far the leading country with 36.7% (11) of all interventional studies. Also in the USA (16.7%, 5), Japan (13.4%, 4), and South Korea (10.0%, 3) several interventional studies have been performed (Fig. 1c and f). The distribution of observational clinical studies across the globe was as follows: 41.6% (42) of the trials took place in the USA, 16.8% (17) in France, 7.9% (8) in Japan, 5.9% (6) in the UK, 6.9% (7) in Israel, 5.0% (5) in Germany and 5.0% (5) in China (see Fig. 1d and g). These results indicate that, although most studies are performed in the USA, a magnitude of these studies have an observational character. In China much less studies are performed in total, however, with the majority of them being interventional. This trend can also be observed for other Asian countries, such as Japan or South Korea. In total, all studies together comprise 15,540 participants. Interventional studies involved 15.0 (±15.0) participants on average, compared to an average of 149.4 (±389.1) participants in observational studies. It therefore becomes obvious, that most study participants can be found in countries, in which a particularly large number of observational clinical studies were performed. 50.2% (7798) of all participants were included into studies in the USA, followed by 20.2% (3139) in the UK and 10.2% (1585) in France (see Fig. 1e). China, South Korea and Brazil are the only countries in which both, the amount of study participants and the number of studies, is higher for interventional clinical trials than for observational ones. In European countries the numbers of studies and patients of observational trials clearly exceeds the ones of interventional studies. There are even several European countries, where no interventional study involving PSCs was found at all (e.g., Germany, Italy, and the Netherlands; see Fig. 1h). In addition, it could be observed, that in many countries not a single clinical trial involving PSCs is registered. This applies e.g., to all countries on the African continent, Russia, large parts of Europe, and Southern America.

Fig. 1. Geographic distribution of studies involving human pluripotent stem cells.

Fig. 1

Open in a new tab

a Global distribution of all clinical trials involving human pluripotent stem cells. b Distribution of all clinical trials involving human pluripotent stem cells. c Global distribution of interventional clinical trials involving pluripotent stem cells. d Distribution of observational clinical trials involving pluripotent stem cells. e Global distribution of all study participants. f Global distribution of interventional clinical trials involving pluripotent stem cells. g Global distribution of observational clinical trials involving pluripotent stem cells. h Comparison between interventional and observational clinical trials and study participants. The horizontal axes have logarithmic scales of different sizes.

Target diseases of clinical trials involving pluripotent stem cells

PSCs have been investigated regarding the treatment of various diseases affecting several different organ systems. We, therefore, analyzed all clinical trials obtained using the multistep search algorithm regarding the targeted disease. The diseases were classified according to the Global Burden of Disease Study 201736 (Fig. 2a). Sense organ diseases, more precisely ophthalmic diseases, were targeted in the highest number of clinical trials (24.4%, 32) followed by other non-communicable diseases (22.1%, 29), cardiovascular diseases (14.5%, 19) and neurological disorders (13.0%, 17). For a detailed overview please refer to Fig. 2b.

Fig. 2. Disease categories targeted in clinical trials involving human pluripotent stem cells.

Fig. 2

Open in a new tab

The legend shown on the top right of Fig. 2 is color coordinated with all three pie charts. a Sub-classification of the category “non-communicable diseases”. b Distribution of clinical trials involving pluripotent stem cells dependent on the targeted disease. c Distribution of observational clinical trials dependent on the targeted disease. d Distribution of interventional clinical trials dependent on the targeted disease.

The category “other non-communicable diseases” includes studies focusing on metabolic diseases (6.9% of all studies, 9), genetic syndromes (6.1%, 8), reproductive and urogenital diseases (3.8%, 5), defects of the immune system (2.3%, 3), hematologic disorders (2.3%, 3) and otorhinolaryngologic diseases (0.8%, 1) (Fig. 2a). The category “none” includes studies that are concerned with the assessment of reprogramming processes (2.3% of all studies, 3) the exploration of differentiation mechanisms (2.3%, 3) and cell banking (1.5%, 2). Analysis of the different disease categories involved in observational type clinical trials revealed that mainly the following diseases were targeted: Other non-communicable diseases (25.7%, 26), cardiovascular diseases (16.8%, 17), neurological disorders (12.9%, 13) and sense organ diseases (12.9%, 13) (Fig. 2c). Interventional clinical trials focused on sense organ diseases (63.3%, 19), holding a big lead over neurological disorders (13.3%, 4), other non-communicable diseases (10%, 3), cardiovascular diseases (6.7%, 2), neoplasms (3.3%, 1) and musculoskeletal disorders (3.3%, 1) (Fig. 2d). In summary, ophthalmic diseases are in the main focus of a major part of all clinical trials involving human PSCs, especially regarding interventional studies. If the categories including ophthalmic diseases and neurological disorders are combined, this group represents the majority of interventional PSC clinical trials (76.6%, 23). Trials focusing on ophthalmic diseases, neurological disorders and cardiovascular diseases account for 51.9% (68) of all PSC – studies.

Study duration of clinical trials

The study duration of clinical trials involving PSCs was analyzed according to the information available from the different databases. The mean duration of trials involving hESCs was 5.8 (±5.1) years compared to 5.2 (±4.2) years for studies using hiPSCs (p = 0.635; see Fig. 3 and Supplementary Fig. 1). Clinical trials of the interventional type were significantly shorter (3.8 years, ±1.8) compared to studies of the observational type (5.9 years (±5.0), p = 0.002, see Fig. 4 and Supplementary Fig. 2). However, only 106 out of 131 trials could be considered, since the end date was not mentioned in 25 (19.1%) trials.

Fig. 3. Comparison of starting point and study duration dependent on the use of either one of the two stem cell types, hiPSC and hESC.

Fig. 3

Open in a new tab

The blue bars show the starting point and study duration of clinical studies involving hESCs, the orange bars depict the same information for studies involving hiPSC. The green dashed line shows the time of data collection. The x axis shows the time in years, the y axis shows the study numbers. A list of the respective studies can be found in Supplementary Table 1.

Fig. 4. Comparison of starting point and (scheduled) study duration dependent on the study design.

Fig. 4

Open in a new tab

The blue bars show the starting point and study duration of observational clinical studies, the orange bars depict the same information for interventional clinical trials. The green dashed line shows the time of data collection. The x axis shows the time in years, the y axis shows the study numbers. A list of the respective studies can be found in Supplementary Table 1.

Type of study and type of stem cells used

77.1% (101) of all clinical trials involving human PSCs were observational, while 22.9% (30) were interventional. In 73.3% (22) of interventional studies hESCs were used, while iPSCs were involved in only 26.7% (8). The origin of the cells was allogeneic in 93.3% (28) and autologous in 6.7% (2). However, when it comes to observational clinical trials, the frequency of the used stem cell type is vice versa. In these studies, hESCs were used in only 10.9% (11), while iPSCs were employed in 89.1% (90). The distribution of all clinical trials dependent on the characteristics interventional/observational and hESC/iPSC is summarized in Fig. 5a. In-depth analysis of the geographical distribution of clinical trials using different types of hPSCs revealed that most studies involving hESCs were conducted in China (33.3%; 11), followed by the USA (27.3%, 9), Israel (12.2%, 4), the UK (9.1%, 3), and South Korea (9.1%, 3) (see Fig. 5b). Concerning clinical trials involving hiPSC, 38.4 % (38) were performed in the USA, 17.2% (17) in France, and 12.1% (12) in Japan (see Fig. 5c).

Fig. 5. Usage of pluripotent stem cell types (hESC and iPSC) dependent on geographic distribution and study design.

Fig. 5

Open in a new tab

a Distribution of all clinical trials and interventional and observational trials respectively, dependent on the usage of hESC or hiPSC. b Choropleth map presenting the geographic distribution of all clinical trials involving hESCs. c Choropleth map presenting the geographic distribution of all clinical trials involving hiPSCs.

Study design and clinical study phase of interventional trials

All interventional studies were open label, non-randomized (100.0%, 30). 90.0% (27) were carried out in one center and 10.0% (3) were multi-center studies. The studies comprised one single arm in 43.3% (14), in 40% (13) the trials enclosed two or more intervention groups, each receiving treatment with pluripotent stem cells (or cells derived from pluripotent stem cells), 6.7% (2) of the studies included a group without intervention and 3.3% (1) a historical control.

In 30% (9) the trial was categorized as Phase I study by the authors, in 50.0% (15) as Phase I/II, in 6.7% (2) the authors declared that this categorization is not applicable and in 13.3% (4) no information regarding the clinical study phase was given. For details on interventional studies please refer to Table 1 and Supplementary Table 2.

Table 1.

Characteristics of interventional clinical trials involving pluripotent stem cells.

ID number Title Cell type Origin Target disease Country or area No. patients enrolled Intervention Status (2019)
NCT03222453 Thalassemia treatment based on the stem cell technology hiPSC Autologous Beta-thalassemia China 2 Injection of hematopoietic stem cells Results submitted to ClinicalTrials.gov
NCT01674829 A Phase I/IIa, open-label, single-center, prospective study to determine the safety and tolerability of sub-retinal transplantation of human embryonic stem cell-derived retinal pigmented epithelial(MA09-hRPE) cells in patients with advanced dry age-related macular degeneration hESC-derived RPE; MA09-hRPE Allogeneic Dry age-related macular degeneration South Korea 12 Sub-retinal Transplantation Active, not recruiting
NCT02903576 Stem cell therapy for outer retinal degenerations hESC-derived RPE Allogeneic Age-related macular degeneration, Stargardt’s disease or exudative age-related macular degeneration Brazil 18 Injection of hESC-RPE in suspension versus injection of hESC-RPE seeded in a substrate Not yet reported, recruitment status unknown
NCT01625559 Safety and tolerability of MA09-hRPE cells in patients with Stargardt’s macular dystrophy (SMD) hESC-derived RPE cells (MA09-hRPE) Allogeneic Stargardt’s macular dystrophy South Korea 3 Sub-retinal transplantation Not yet reported, recruitment status unknown
NCT03763136 Treating heart failure with hPSC-CMs hiPSCs- derived cardiomyocytes Allogeneic Heart failure China 5 Injection into the myocardium Recruiting
NCT03046407 Treatment of dry age-related macular degeneration disease with retinal pigment epithelium-derived from human embryonic stem cells hESC-derived RPE Allogeneic Dry age-related macular degeneration China 10 Subretinal transplantation Recruiting
NCT03944239 Safety and efficacy of subretinal transplantation of clinical human embryonic stem cell-derived retinal pigment epitheliums in treatment of retinitis pigmentosa hESC-derived RPE Allogeneic Retinitis pigmentosa China 10 Subretinal transplantation Recruiting
NCT03482050 Study to evaluate transplantation of astrocytes derived from human embryonic stem cells, in patients with amyotrophic lateral sclerosis hESC-derived astrocytes Allogeneic Amyotrophic lateral sclerosis Israel 21 intrathecal (spinal) injection Recruiting
NCT02755428 Subretinal transplantation of retinal pigment epitheliums in treatment of age-related macular degeneration diseases hESC-derived RPE Allogeneic Dry age-related macular degeneration China 10 Subretinal transplantation Recruiting
NCT03119636 Safety and efficacy study of human ESC-derived neural precursor cells in the treatment of Parkinson’s disease hESC- derived neural precursor cells Allogeneic Parkinson’s disease China 50 Stereotaxic intra-striatal injection Recruiting
NCT02286089 Safety and efficacy study of opregen for treatment of advanced dry-form age-related macular degeneration hESC-derived RPE Allogeneic Age-related macular degeneration USA + Israel 24 Subretinal transplantation Recruiting
NCT03877471 Mesenchymal stem cells - like cell transplantation in women with primary ovarian insufficiency hESC-derived MSC-like cells Allogeneic Primary ovarian insufficiency China 28 Injection into ovaries bilaterally Recruiting
NCT03841110 FT500 as monotherapy and in combination with immune checkpoint inhibitors in subjects with advanced solid tumors iPSC-derived NK cell cancer immunotherapy Allogeneic Advanced solid tumors USA 76 Recruiting
JPRN-UMIN000032989 Clinical trial of human (allogeneic) induced pluripotent stem cell-derived cardiomyocyte sheet for severe cardiomyopathy iPS cell-derived cardiomyocytes Allogeneic Ischemic cardiomyopathy Japan 3 iPS cell-derived cardiomyocyte sheet transplantation Recruitment complete
NCT03963154 Interventional study of implantation of hESC-derived RPE in patients With RP due to monogenic mutation hESC-derived RPE Allogeneic Retinitis pigmentosa due to monogenic mutation France 12 single central subretinal implantation of a hESC-derived RPE monolayer in one eye Recruiting
NCT03305029 The safety and tolerability of sub-retinal transplantation of SCNT-hES-RPE cells in patients with advanced Dry AMD SCNT hESC-derived RPE Allogeneic Dry age-related macular degeneration South Korea 3 Subretinal transplantation Recruitment status unknown
NCT02057900 Transplantation of human embryonic stem cell-derived progenitors in severe heart failure (ESCORT) hESC- derived CD15+Isl-1+ progenitors Allogeneic Ischemic heart disease France 10 fibrin gel embedding hESC-derived CD15+Isl-1+ progenitors Completed, results published18
NCT01469832 Safety and tolerability of sub-retinal transplantation of human embryonic stem cell-derived retinal pigmented epithelial (hESC-RPE) cells in patients with Stargardt’s Macular Dystrophy (SMD) hESC-derived RPE cells (MA09-hRPE) Allogeneic Stargardt’s macular dystrophy UK 12 Subretinal injection Completed, results published61
NCT01345006 Sub-retinal transplantation of hESC-derived RPE(MA09-hRPE) cells in patients with Stargardt’s Macular Dystrophy hESC-derived RPE cells (MA09-hRPE) Allogeneic Stargardt’s macular dystrophy USA 13 Subretinal injection Completed, results published5,62
NCT01344993 Safety and tolerability of sub-retinal transplantation of hESC-derived RPE (MA09-hRPE) cells in patients with advanced dry age-related macular degeneration hESC-derived RPE cells (MA09-hRPE) Allogeneic Dry age-related macular degeneration USA 13 Subretinal injection Completed, results published5,62
JPRN-UMIN000011929 A Study of transplantation of autologous induced pluripotent stem cell (iPSC) derived retinal pigment epithelium (RPE) cell sheet in subjects with exudative age-related macular degeneration hiPSC-derived RPE Autologous Exudative age-related macular degeneration Japan 6 Transplantation of iPSC-derived RPE cell sheet Complete, results published19
NCT02590692 Study of subretinal implantation of human embryonic stem cell-derived RPE cells in advanced Dry AMD hESC-derived RPE Allogeneic Dry age-related macular degeneration USA 16 Subretinal implantation Active, not recruiting
NCT03839238 Safety observation on hESC-derived MSC like cell for the meniscus injury hESC- derived MSC like cell Allogeneic Meniscus injury China 18 hESC- derived MSC like cells Active, not recruiting
NCT02923375 A study of CYP-001 for the treatment of steroid-resistant acute graft versus host disease iPSC- derived MSCs Allogeneic Graft vs host disease Australia + UK 16 IV infusion on two occasions Active, not recruiting
NCT01691261 A study of implantation of retinal pigment epithelium in subjects with acute wet age-related macular degeneration hESC-derived RPE Allogeneic Age-related macular degeneration UK 2 Implantation of RPE monolayer immobilized on a polyester membrane. Active, not recruiting
NCT02749734 Clinical study of subretinal transplantation of human embryo stem cell-derived retinal pigment epitheliums in treatment of macular degeneration diseases hESC-derived RPE Allogeneic Macular degeneration Stargardt’s macular dystrophy China 15 Subretinal transplantation Recruitment status unknown
JPRN-UMIN000033564 Kyoto trial to evaluate the safety and efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson’s disease hiPSC-derived dopaminergic progenitors Parkinson’s disease Japan 7 Transplantation into the corpus striatum Recruitment suspended
JPRN-UMIN000026003 A Study of transplantation of allogenic induced pluripotent stem cell (iPSC) derived retinal pigment epithelium (RPE) cell suspension in subjects with neovascular age-related macular degeneration iPSC-derived RPE Allogeneic Neovascular age-related macular degeneration Japan 5 Subretinal transplantation Recruitment complete; follow-up continuing
ChiCTR-OCB-15007054 Clinical study of subretinal transplantation of clinical human embryonic stem cells derived retinal pigment epitheliums in treatment of dry age-related macular degeneration diseases hESC-derived RPE Allogeneic Dry age-related macular degeneration China 10 Subretinal transplantation Recruiting
ChiCTR-OCB-15005968 The clinical trial of human embryonic stem cell-derived epithelial cells transplantation in the treatment of severe ocular surface diseases hESC-derived epithelial cells Allogeneic Severe ocular surface disease China 20 Corneal-epithelium-like-cell transplantation Recruiting
Open in a new tab

hESC human embryonic stem cells, hiPSC human induced pluripotent stem cell, RPE retinal pigment epithelium, hRPE human retinal pigment epithelium, MSC mesenchymal stem cell, UK United Kingdom.

Discussion

Human pluripotent stem cells hold great potential for novel therapeutic approaches to regenerate or replace functionally impaired tissues20,37–40. In addition, the use of autologous cells for in vitro disease modeling and drug testing without re-transplantation into the host has also become an increasingly important scientific branch of regenerative medicine41,42. Following the initial report by Yamanaka and Takahashi in 20069, the number of scientific publications on pluripotent stem cells has virtually exploded over the past years. Consequently, it can be assumed that also the number of clinical trials, in the sense of studies on PSCs involving human subjects, may have been increasing in parallel. While scientific publications represent an indicator for the scientific interest in a certain technology, the number of clinical trials indicates how many attempts have been made to actually translate the technology from the bench to the clinical phase as it represents the final stage prior to a potential standard use in human patients. However, the published information contained in research studies is generally limited by a significant publication bias, implying that negative results may not be published at all due to rejection by editors or reviewers, competing interests or lack of interest to publish43,44. In addition, results may not be published due to a lack of interest by the sponsoring institution. Therefore, we have focused on the comprehensive analysis of the past and present status of clinical trials on pluripotent stem cells to generate an overview on the actual number and content of clinical trials involving this promising technology.

So far, several studies have been focusing on the trends in clinical trials involving “stem cells” in general. Monsarrat et al. published an analysis of clinical trials involving stem cells listed on “ClinicalTrials.gov”. In this work he assessed the different organ systems and diseases involved in these trials, including comparisons between different study phases and stem cell types31. Squillaro et al. focused on clinical trials involving “mesenchymal stem cells”, investigating different clinical findings and therapeutic effects33. Fung et al. analyzed to which extent authors of clinical trials involving stem cells had already published their results by using PubMed, Embase and Google Scholar30. However, so far, there is no comprehensive, systematic analysis addressing the geographic distribution, concerned organ systems and used cell types of clinical trials on human pluripotent stem cells. In addition, these previous studies were either limited regarding the type of stem cell used, e.g., focusing on “multipotent stem cells” only33, and/or their search was only conducted in one database (mostly “ClinicalTrials.gov”)30–33. Even though “ClinicalTrials.gov” is the largest database for clinical trials and represented in more than 200 countries around the globe, a search query in this database does not guarantee completeness. Alternative meta-databases collecting data from even more countries and databases, such as the ICTRP database from the WHO, have not been included in several studies45, which implies that some trials may have been missed.

Therefore, in the present analysis, we complemented our systematic search on “ClinicalTrials.gov” by using the ICTRP database of the WHO as well as by performing a search at each individual platform that is included in the ICTRP repository. This multi-step approach should enable the most complete overview on clinical trials involving “pluripotent stem cells”. Following a stringent inclusion/exclusion procedure, 131 studies remained that could be classified as clinical trials involving PSCs. The magnitude of these studies (77.1%) was of observational nature, which means that no cells were transplanted into patients for therapeutic use. These studies mainly included trials where cells were isolated from patients or volunteers for the subsequent use as part of reprogramming experiments. This also implies that only a minority of studies (22.9%) were of an interventional study type, where cells were actually transplanted into patients for therapeutic purposes. From the view point of translational medicine, these interventional studies are of greater interest, since the introduction of the iPSC technology was associated with a significant hope for future clinical use in the sense of cellular transplantation8,46–49. While the total number of clinical trials involving iPSCs (74.8%) was substantially higher than the ones involving ESCs (25.2%), the picture changes completely when focusing on interventional studies. Here, in the majority (73.3%) of trials ESCs were involved and only in few studies (26.7%) iPSCs were used for the intervention. However, when considering the increasing number of trials on iPSCs, a future switch towards interventional iPSC trials might just be a matter of time. In particular the introduction of non-integrating transgene-free reprogramming approaches may further support the clinical translation of the iPSC technology as the issue of in situ carcinogenicity of iPSCs due to remaining viral particles may be solved by these technologies50.

Also, when focusing on the geographical regions, where the studies have been performed, it becomes obvious that there are substantial differences between different study types. While regarding observational studies the greatest part of all trials was performed in the USA (41.6%) and in France (16.8%), the majority of interventional studies was performed in Asian countries (China 36.7%, Japan 13.3%, South Korea 10.0%). The major reasons for this may be seen in the differences in legal and/or regulatory restrictions on ESC research in Western countries, in different research policies as well as in different national ethical regulations of different countries concerning pluripotent stem cell research7,51–54. In many countries of the European region, the harvest of stem cells from a human embryo for research purposes is prohibited, however, in some countries research can be conducted using imported pluripotent cells55. In the USA, stem cell research is regulated by National Academies (NAS) Guidelines, which allows the derivation of ESC lines from human embryos, however, additionally, some US states have adopted their own regulations56. In China, where research on human embryos and cloning for therapeutic purposes is in general permitted, state regulations established in 2015 attempt to limit clinical trials using stem cells to research centers57,58. Other potential factors might be the differences in the focus of research institutions on a particular topic, the policies of funding agencies as well as the societal perceptions on pluripotent stem cell research in general59.

When focusing on the targeted diseases of PSC clinical trials, it becomes evident that “sense organ diseases”, more precisely ophthalmic diseases, are targeted in 24.4% (32) of all studies. Regarding the group of interventional studies even 63.3% of all trials addressed the eyes. The majority of observational studies was concerned with other non-communicable diseases (25.7%, 26), cardiovascular diseases (16.8%, 17), neurological disorders (12.9%, 13), and ophthalmic diseases (12.9%, 13). In particular the relatively high proportion of - especially interventional - clinical trials in the field of ophthalmology is striking. A major reason for this may not only lie in the different ocular pathologies that profit from cellular replacement, it may also be due to anatomic circumstances, since the eye is easily accessible for stem cell transplantation and in the case of adverse events life-threatening complications are scarce4,60. This lack of fatal complications represents a major advantage over diseases concerning other organ systems, such as cardiovascular diseases, when introducing a new therapeutic concept. However, also the pathophysiology of targeted ophthalmologic diseases forms the basis for the broader clinical investigation of hPSCs in this field. Ophthalmologic diseases, such as Stargardt’s macular dystrophy or atrophic age-related macular degeneration, are predominantly treated as part of these clinical trials5,19. These diseases share the pathophysiologic element of progressive cellular degeneration that may be treated by stem cells replacing the impaired tissues5. In the end, it is the combination of all the reasons mentioned above that may form the basis for the disproportionally high fraction of PSC interventional clinical trials focusing on ophthalmologic diseases4,60.

Interestingly, an in-depth analysis of the group of interventional studies also revealed several limitations of these recent clinical trials on pluripotent stem cells. This includes a lack of placebo control groups (0%) or untreated control groups (6.7%), a lack of long-term follow-up periods (only one study with published results had a follow-up of >12 months) and a lack of reporting (only 27.8% of all interventional trials without active recruitment have already been published in a peer-reviewed journal). A major limitation of the present analysis, as well as of all studies focusing on the analysis of clinical trial databases in general, might be a reporting bias. In particular regarding observational studies, it has to be assumed that not all studies may have been registered on public databases, limiting the representativeness of the data on this type of trials.

In summary, the present analysis shows that, although a large series of clinical trials involving PSCs has been registered in public databases, only a small part has been focusing on the actual transplantation of cells. The greatest part of these interventional studies was focusing on the use of ESCs in the field of ophthalmology. Therefore, in spite of the “hype” on iPSC research in recent years also fostered by the Nobel Prize in 2012, the iPSC technology has not reached the clinical investigational phase on a broader scale yet. The future will tell us, if the iPSC technology will ultimately overcome the challenges associated with their clinical use - such as carcinogenicity, lack of in situ integration49,61, genomic instability27, immunological rejection28 or lack of quality control criteria62 - and whether it will finally make its way into routine clinical use.

Methods

Systematic search of databases

The aim of the study was to perform a comprehensive analysis of all clinical trials involving pluripotent stem cells based on a defined sequence of database searches. First a search was performed in the database “ClinicalTrials.gov” using the search terms “pluripotent” OR “pluripotent stem cell” OR “induced pluripotent stem cell” OR “iPSC” OR “embryonic stem cell”. In parallel a search was performed on the “International Clinical Trials Registry Platform” (ICTRP) using the identical search terms as mentioned above. This primary search was performed in August 2019. The search algorithm is summarized in Supplementary Fig. 3. In total 177 studies were identified at “ClinicalTrials.gov”. Among them, 68 clinical studies had to be excluded because 65 of them did not involve pluripotent stem cells or the employment of pluripotent stem cells was optional. The three remaining studies were excluded since they were withdrawn before enrolling its first participant. This search was complimented by a search on the ICTRP portal site, which is provided by the WHO. This database combines several different national and international databases. These individual databases were searched separately in order to maximize the number of relevant trials identified. Based on the ICTRP portal site 21 additional clinical trials could be added to the final analysis after excluding duplicated search results also obtained from “ClinicalTrials.gov”. The individual search of databases included in the ICTRP-based meta search did only detect one additional relevant clinical trial in the “Australian New Zealand Clinical Trials Registry” (ANZCTR). In total, 131 appropriate clinical trials involving pluripotent stem cells were identified, downloaded and consistently analyzed using Microsoft Excel (Microsoft Inc., USA). The world maps were created using Microsoft Excel (Microsoft Inc., USA). Microsoft product screen shot(s) of the world maps were reprinted with permission from Microsoft Corporation. The following properties of the 131 studies have been content of the analysis: “Registration number” (NCT number, if possible), “study title”, “recruitment status”, “study type” (observational or interventional), “type of stem cell” (hESC or hiPSC), “study target”, “target disease”, “corresponding organ system”, “sponsor”, “location”,”study start”, “estimated study completion” and “number enrolled”.

Content analysis of clinical trials

The studies were generally classified as observational or interventional study types by the study authors. However, in some cases the “interventional” type of the study mentioned on the database was derived from an “invasive” cell harvesting procedure only, such as a blood draw or a skin biopsy. In our analysis the term “interventional” study type was uniformly reserved for studies, in which cells were (re)transplanted into a patient using an interventional procedure by itself. An invasive cell harvesting procedure, such as a blood draw, was not sufficient to fulfill this criterion. Accordingly, a clinical trial was assigned to the “observational” study type, if the intervention only served to obtain primary cells. Based on these considerations, 20 apparently “interventional” clinical trials were re-categorized as “observational” studies. In two supposedly “observational” clinical trials it was the other way round, they were re-categorized as “interventional” clinical trials. The search for clinical trials and parts of the results section were generated as part of a medical diploma thesis of one of the first authors of this publication.

Biostatistical analysis

All data are presented in percentage (and absolute numbers). The study duration of different study types was compared using an unpaired Student’s t test. P values < 0.05 were considered statistically significant. All analyses were performed using either Microsoft Excel (Microsoft Inc., USA) or SPSS 24.0 (SPSS Inc., USA). Individual sub-groups were compared graphically in the form of pie or bar charts. In addition, choropleth maps, generated using Microsoft Excel (Microsoft Inc., USA), were used to indicate the geographical distribution of the involved studies.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Supplementary information

Supplementary Information (368.8KB, pdf)
Reporting Summary (66.8KB, pdf)

Acknowledgements

We would like to thank the following funding institutions for their support: Austrian Science Fund (FWF; P-30615), Medical Scientific Fund of the Mayor of the City of Vienna (MA-GMWF-501912-2019), Vienna Science and Technology Fund (WWTF; LS18-080) and institutional funding of the Medical University of Vienna, Austria.

Author contributions

J.D. carried out the analysis of the data, helped to gather the original data and to draft the manuscript. D.R. helped to gather the original data and designed the figures. J.D. and D.R. contributed equally to the manuscript and therefore share the first authorship (“co-first authors”). B.W. designed and coordinated the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Data availability

The data contained in this manuscript was derived from the following publicly available databases: “ClinicalTrials.gov” and the ICTRP database of the WHO (and its individual databases).

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Julia Deinsberger, David Reisinger.

Supplementary information

Supplementary information is available for this paper at 10.1038/s41536-020-00100-4.

References

  • 1.Abu-Dawud R, Graffmann N, Ferber S, Wruck W, Adjaye J. Pluripotent stem cells: induction and self-renewal. Philosophical transactions of the Royal Society of London. Series B Biol. Sci. 2018;373:1750. doi: 10.1098/rstb.2017.0213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Kimbrel EA, Lanza R. Pluripotent stem cells: the last 10 years. Regen. Med. 2016;11:831–847. doi: 10.2217/rme-2016-0117. [DOI] [PubMed] [Google Scholar]
  • 3.Mahla RS. Stem cells applications in regenerative medicine and disease therapeutics. Int. J. Cell Biol. 2016;2016:24. doi: 10.1155/2016/6940283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.da Cruz L, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat. Biotechnol. 2018;36:328–337. doi: 10.1038/nbt.4114. [DOI] [PubMed] [Google Scholar]
  • 5.Schwartz SD, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509–516. doi: 10.1016/S0140-6736(14)61376-3. [DOI] [PubMed] [Google Scholar]
  • 6.Shroff G. Human embryonic stem cell therapy in chronic spinal cord injury: a retrospective study. Clin. Transl. Sci. 2016;9:168–175. doi: 10.1111/cts.12394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.de Wert G, Mummery C. Human embryonic stem cells: research, ethics and policy. Hum. Reprod. 2003;18:672–682. doi: 10.1093/humrep/deg143. [DOI] [PubMed] [Google Scholar]
  • 8.Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481:295–305. doi: 10.1038/nature10761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676. doi: 10.1016/j.cell.2006.07.024. [DOI] [PubMed] [Google Scholar]
  • 10.Hofrichter M, et al. Comparative performance analysis of human iPSC-derived and primary neural progenitor cells (NPC) grown as neurospheres in vitro. Stem Cell Res. 2017;25:72–82. doi: 10.1016/j.scr.2017.10.013. [DOI] [PubMed] [Google Scholar]
  • 11.Generali M, et al. Autologous endothelialized small-caliber vascular grafts engineered from blood-derived induced pluripotent stem cells. Acta Biomaterialia. 2019;97:333–343. doi: 10.1016/j.actbio.2019.07.032. [DOI] [PubMed] [Google Scholar]
  • 12.Sundberg M, et al. Improved cell therapy protocols for Parkinson’s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells. 2013;31:1548–1562. doi: 10.1002/stem.1415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Takahashi J. Strategies for bringing stem cell-derived dopamine neurons to the clinic: The Kyoto trial. Prog. Brain Res. 2017;230:213–226. doi: 10.1016/bs.pbr.2016.11.004. [DOI] [PubMed] [Google Scholar]
  • 14.Pagliuca FW, et al. Generation of functional human pancreatic β cells in vitro. Cell. 2014;159:428–439. doi: 10.1016/j.cell.2014.09.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Wang Y, et al. Engineering vascular tissue with functional smooth muscle cells derived from human iPS cells and nanofibrous scaffolds. Biomaterials. 2014;35:8960–8969. doi: 10.1016/j.biomaterials.2014.07.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wimmer RA, et al. Human blood vessel organoids as a model of diabetic vasculopathy. Nature. 2019;565:505–510. doi: 10.1038/s41586-018-0858-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Stoddard-Bennett T, Reijo Pera R. Treatment of Parkinsonas disease through personalized medicine and induced pluripotent stem cells. Cells. 2019;8:26. doi: 10.3390/cells8010026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Menasché P, et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 2018;71:429–438. doi: 10.1016/j.jacc.2017.11.047. [DOI] [PubMed] [Google Scholar]
  • 19.Mandai M, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 2017;376:1038–1046. doi: 10.1056/NEJMoa1608368. [DOI] [PubMed] [Google Scholar]
  • 20.Braganca J, Lopes JA, Mendes-Silva L, Almeida Santos JM. Induced pluripotent stem cells, a giant leap for mankind therapeutic applications. World J. Stem Cells. 2019;11:421–430. doi: 10.4252/wjsc.v11.i7.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Zhu H, Lensch MW, Cahan P, Daley GQ. Investigating monogenic and complex diseases with pluripotent stem cells. Nat. Rev. Genet. 2011;12:266–275. doi: 10.1038/nrg2951. [DOI] [PubMed] [Google Scholar]
  • 22.Fu X, Xu Y. Challenges to the clinical application of pluripotent stem cells: towards genomic and functional stability. Genome Med. 2012;4:55. doi: 10.1186/gm354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Quinlan AR, et al. Genome sequencing of mouse induced pluripotent stem cells reveals retroelement stability and infrequent DNA rearrangement during reprogramming. Cell Stem Cell. 2011;9:366–373. doi: 10.1016/j.stem.2011.07.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Laurent LC, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell. 2011;8:106–118. doi: 10.1016/j.stem.2010.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer. 2011;11:268–277. doi: 10.1038/nrc3034. [DOI] [PubMed] [Google Scholar]
  • 26.Zhao T, Zhang Z-N, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474:212–215. doi: 10.1038/nature10135. [DOI] [PubMed] [Google Scholar]
  • 27.Yoshihara M, Oguchi A, Murakawa Y. Genomic instability of iPSCs and challenges in their clinical applications. Adv. Exp. Med. Biol. 2019;1201:23–47. doi: 10.1007/978-3-030-31206-0_2. [DOI] [PubMed] [Google Scholar]
  • 28.Liu X, Li W, Fu X, Xu Y. The immunogenicity and immune tolerance of pluripotent stem cell derivatives. Front. Immunol. 2017;8:645. doi: 10.3389/fimmu.2017.00645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Fujikawa T, et al. Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am. J. Pathol. 2005;166:1781–1791. doi: 10.1016/S0002-9440(10)62488-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Fung M, Yuan Y, Atkins H, Shi Q, Bubela T. Responsible translation of stem cell research: an assessment of clinical trial registration and publications. Stem Cell Rep. 2017;8:1190–1201. doi: 10.1016/j.stemcr.2017.03.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Monsarrat P, et al. An innovative, comprehensive mapping and multiscale analysis of registered trials for stem cell-based regenerative medicine. Stem Cells Transl. Med. 2016;5:826–835. doi: 10.5966/sctm.2015-0329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Negoro T, Takagaki Y, Okura H, Matsuyama A. Trends in clinical trials for articular cartilage repair by cell therapy. NPJ Regen. Med. 2018;3:17. doi: 10.1038/s41536-018-0055-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transpl. 2016;25:829–848. doi: 10.3727/096368915X689622. [DOI] [PubMed] [Google Scholar]
  • 34.ClinicalTrials.gov. Vol. 2020 (https://clinicaltrials.gov/).
  • 35.International Clinical Trials Registry Platform (ICTRP) Vol. 2020 (https://www.who.int/ictrp/en/).
  • 36.James SL, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858. doi: 10.1016/S0140-6736(18)32279-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Cyranoski D. ‘Reprogrammed’ stem cells approved to mend human hearts for the first time. Nature. 2018;557:619–620. doi: 10.1038/d41586-018-05278-8. [DOI] [PubMed] [Google Scholar]
  • 38.Stoddard-Bennett T, Reijo Pera R. Treatment of Parkinson’s disease through personalized medicine and induced pluripotent stem cells. Cells. 2019;8:26. doi: 10.3390/cells8010026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Wu J, Izpisua Belmonte JC. Dynamic pluripotent stem cell states and their applications. Cell Stem Cell. 2015;17:509–525. doi: 10.1016/j.stem.2015.10.009. [DOI] [PubMed] [Google Scholar]
  • 40.Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic. Nat. Rev. Mol. Cell Biol. 2016;17:194–200. doi: 10.1038/nrm.2016.10. [DOI] [PubMed] [Google Scholar]
  • 41.Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat. Rev. Mol. Cell Biol. 2016;17:170–182. doi: 10.1038/nrm.2015.27. [DOI] [PubMed] [Google Scholar]
  • 42.Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat. Rev. Genet. 2019;20:377–388. doi: 10.1038/s41576-019-0100-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Mlinarić A, Horvat M, Šupak Smolčić V. Dealing with the positive publication bias: why you should really publish your negative results. Biochemia Med. 2017;27:030201. doi: 10.11613/BM.2017.030201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nair AS. Publication bias-importance of studies with negative results! Indian J. Anaesth. 2019;63:505–507. doi: 10.4103/ija.IJA_142_19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Negoro T, et al. Trends in clinical trials for stroke by cell therapy: data mining ClinicalTrials.gov and the ICTRP portal site. npj Regenerative Med. 2019;4:20. doi: 10.1038/s41536-019-0082-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Nordin N, et al. Induced pluripotent stem cells: history, properties and potential applications. Med. J. Malays. 2011;66:4–9. [PubMed] [Google Scholar]
  • 47.Omole AE, Fakoya AOJ. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications. PeerJ. 2018;6:e4370. doi: 10.7717/peerj.4370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Liu J. Induced pluripotent stem cell-derived neural stem cells: new hope for stroke? Stem Cell Res. Ther. 2013;4:115. doi: 10.1186/scrt326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Lu X, Zhao T. Clinical therapy using iPSCs: hopes and challenges. Genom. Proteom. Bioinforma. 2013;11:294–298. doi: 10.1016/j.gpb.2013.09.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Slamecka J, et al. Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions. Cell Cycle. 2016;15:234–249. doi: 10.1080/15384101.2015.1121332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Al-Sayyari RA. Ethical aspects of stem cells research. Saudi J. Kidney Dis. Transplant. 2005;16:606–611. [PubMed] [Google Scholar]
  • 52.Volarevic V, et al. Ethical and safety issues of stem cell-based therapy. Int. J. Med. Sci. 2018;15:36–45. doi: 10.7150/ijms.21666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Neaves W. The status of the human embryo in various religions. Development. 2017;144:2541–2543. doi: 10.1242/dev.151886. [DOI] [PubMed] [Google Scholar]
  • 54.Lo B, Parham L. Ethical issues in stem cell research. Endocr. Rev. 2009;30:204–213. doi: 10.1210/er.2008-0031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Regulation of stem cell research in Europe. Vol. 2020 (ed. Mahalatchimy, A.) (https://www.eurostemcell.org).
  • 56.Hynes RO. US policies on human embryonic stem cells. Nat. Rev. Mol. Cell Biol. 2008;9:993–997. doi: 10.1038/nrm2528. [DOI] [PubMed] [Google Scholar]
  • 57.Liao L, Li L, Zhao RC. Stem cell research in China. Philos. Trans. R. Soc. Lond. Ser. B, Biol. Sci. 2007;362:1107–1112. doi: 10.1098/rstb.2007.2037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Rosemann A, Sleeboom-Faulkner M. New regulation for clinical stem cell research in China: expected impact and challenges for implementation. Regenerative Med. 2016;11:5–9. doi: 10.2217/rme.15.80. [DOI] [PubMed] [Google Scholar]
  • 59.Dajani R. Jordan’s stem-cell law can guide the Middle East. Nature. 2014;510:189–189. doi: 10.1038/510189a. [DOI] [PubMed] [Google Scholar]
  • 60.Takahashi M. Retinal cell therapy using iPS cells. Nippon Ganka Gakkai Zasshi. 2016;120:210–224. [PubMed] [Google Scholar]
  • 61.Mehat MS, et al. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration. Ophthalmology. 2018;125:1765–1775. doi: 10.1016/j.ophtha.2018.04.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Schwartz SD, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379:713–720. doi: 10.1016/S0140-6736(12)60028-2. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information (368.8KB, pdf)
Reporting Summary (66.8KB, pdf)

Data Availability Statement

The data contained in this manuscript was derived from the following publicly available databases: “ClinicalTrials.gov” and the ICTRP database of the WHO (and its individual databases).

Articles from NPJ Regenerative Medicine are provided here courtesy of Nature Publishing Group

RESOURCES